11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
Apellis Pharmaceuticals Inc. (APLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 12,222,222 | $390,011,104 | +10% | 5.51% |
| 2. | EcoR1 Capital Oleg Nodelman | 11,890,843 | $379,436,800 | 14.34% | |
| 3. | Deep Track Capital David Kroin | 4,274,921 | $136,412,729 | -3% | 5.08% |
| 4. | Octagon Capital Advisors Ting Jia | 3,006,980 | $95,952,732 | 15.78% | |
| 5. | Siren L.L.C. Raymond Debbane | 2,816,258 | $89,866,793 | 3.97% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 250,000 | Large Shareholder | 12,806,342 | 2021-11-18 | Filing | |
| $31.81 | 5,000 | Director | 5,000 | 2020-05-08 | Filing | |
| $37.00 | 540,540 | Large Shareholder | 12,556,342 | 2020-01-13 | Filing | |
| $29.71 | 11,699 | Officer | 11,699 | 2019-08-29 | Filing | |
| $17.00 | 441,176 | Large Shareholder | 12,015,802 | 2019-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.82 | 183 | Officer | 47,955 | 2025-03-17 | Filing | |
| $25.10 | 5,569 | 138,730 | 2025-03-05 | Filing | ||
| $28.54 | 363 | Officer | 83,945 | 2025-02-11 | Filing | |
| $29.52 | 695 | Officer | 144,299 | 2025-01-29 | Filing | |
| $29.52 | 695 | Officer | 84,050 | 2025-01-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 124,454 | $2,721,755 | 0% | |
| 2. | 44,166 | $965,910 | 0.04% | |
| 3. | 42,534 | $930,219 | 0.04% | |
| 4. | 33,762 | $738,375 | 0.01% | |
| 5. | Imc-chicago, LlcCALL | 14,200 | $310,554 | 0% |
News See All
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript February 28, 2025Apellis Pharmaceuticals, Inc. beats earnings expectations.
10 Oversold Pharma Stocks to Buy According to Analysts
On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity...
12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022.
10 Top Insider Stock Buys And Sells In January
Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market where stock prices, most commonly of small-cap stocks, rise in the ...
10 Mid-Cap Stocks Insiders Are Selling Recently
Why should investors analyze insider trading activity? Insiders, or people in high positions within a company—such as executives and directors—can have crucial insights into the company’s strategic...
Should You Hold Apellis Pharmaceuticals (APLS)?
PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript November 5, 2024Apellis Pharmaceuticals, Inc. misses on earnings expectations.
Should You Hold Apellis Pharmaceuticals (APLS)?
PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Billionaire Hedge Funds
